Use of Levosimendan vs. Dopamine in Cardiogenic Shock

Article Sidebar

PDF
Published: Oct 7, 2023
DOI: https://doi.org/10.47191/ijmscrs/v3-i10-16
Keywords:
levosimendan, dopamine, cardiogenic shock, inotropes, management.

Main Article Content

Cristian Josué Sosa Álvarez
Departamento de medicina interna, Instituto Mexicano del Seguro Social, Jesús María, Aguascalientes, Mexico
Karen Alejandra Zebadúa Ramírez
Departamento de medicina interna, Instituto Mexicano del Seguro Social, Jesús María, Aguascalientes, Mexico
Jorge Arturo Diaz Cancino
Departamento de medicina interna, Instituto Mexicano del Seguro Social, Mérida, Yucatán, Mexico

Abstract

Cardiogenic shock is a life-threatening condition characterized by severe cardiac dysfunction and hemodynamic instability. The choice of inotropic agent for managing cardiogenic shock is a critical decision for healthcare providers. This comprehensive review assesses the use of levosimendan and dopamine in the management of cardiogenic shock. It explores the epidemiology of cardiogenic shock, the significance of this clinical challenge, and the theoretical framework of inotropic support. Furthermore, it examines risk factors, potential complications, and optimal management strategies. The discussion delves into the comparative efficacy and safety profiles of levosimendan and dopamine, providing insights into their roles in this critical clinical scenario. Finally, the review concludes with a summary of key findings and recommendations for clinical practice.

Article Details

How to Cite
Cristian Josué Sosa Álvarez, Karen Alejandra Zebadúa Ramírez, & Jorge Arturo Diaz Cancino. (2023). Use of Levosimendan vs. Dopamine in Cardiogenic Shock. International Journal of Medical Science and Clinical Research Studies, 3(10), 2205–2207. https://doi.org/10.47191/ijmscrs/v3-i10-16
Issue
Vol. 3 No. 10 (2023): Volume 03 Issue 10 October 2023
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

References

I. Omerovic, E., Råmunddal, T., Albertsson, P., Holmberg, M., Hallgren, P., Boren, J., ... & Matejka, G. (2010). Levosimendan neither improves nor worsens mortality in patients with cardiogenic shock due to ST-elevation myocardial infarction. Vascular health and risk management, 657-663.

II. Padayachee, L. (2007). Levosimendan: the inotrope of choice in cardiogenic shock secondary to takotsubo cardiomyopathy?. Heart, Lung and Circulation, 16, S65-S70.

III. Nativi-Nicolau, J., Selzman, C. H., Fang, J. C., & Stehlik, J. (2014). Pharmacologic therapies for acute cardiogenic shock. Current opinion in cardiology, 29(3), 250-257.

IV. Hu, K., & Mathew, R. (2022). Inotrope and vasopressor use in cardiogenic shock: what, when and why?. Current Opinion in Critical Care, 28(4), 419-425.

V. Buerke, M., & Prondzinsky, R. (2008). Levosimendan in cardiogenic shock: Better than enoximone!. Critical care medicine, 36(8), 2450-2451.

VI. Polyzogopoulou, E., Arfaras-Melainis, A., Bistola, V., & Parissis, J. (2020). Inotropic agents in cardiogenic shock. Current opinion in critical care, 26(4), 403-410.

VII. Delle Karth, G., Buberl, A., Geppert, A., Neunteufl, T., Huelsmann, M., Kopp, C., ... & Heinz, G. (2003). Hemodynamic effects of a continuous infusion of levosimendan in critically ill patients with cardiogenic shock requiring catecholamines. Acta anaesthesiologica scandinavica, 47(10), 1251-1256.